Tru-D is the only UVC disinfection device backed by a CDC-funded, randomized clinical trial* shown to reduce the relative risk of transmission of health care-associated infections by a cumulative 30 percent among patients admitted to the same room when 93% compliance of standard disinfection protocols occurred. Individual hospital results may vary. More Tru-Ds have been deployed to disinfect hospitals across the globe than all other competing lookalike offerings, fighting deadly pathogens such as C. diff, MRSA, VRE, MERS, Ebola and many more. An effective and innovative technology backed by sound science, Tru-D is on a mission to eradicate deadly pathogens making hospitals safer places for patients and staff.
Tru-D’s Philips, low-pressure mercury vapor bulbs provide the most efficient delivery of UVC energy. Unlike any of its competitors, Tru-D safely and effectively destroys all pathogens in its path from one placement in the room without the risk of human error for calculating cycle time or position. Xenon flash lamps and other unmeasured UV lights, while they may use UVC lamps, have no way of calculating the UVC dose needed for each location to determine the positioning or time necessary to disinfect accurately, nor can they reach shadowed or hidden surfaces.
Tru-D’s single placement positioning allows you to work smarter, not harder, implementing seamlessly into any hospital’s workflow. While Tru-D completes a disinfection cycle, environmental services workers are free to complete other tasks, rather than having to move the robot to multiple positions. Once the cleaning cycle is complete, Tru-D automatically shuts down and sends an audio and/or text message alert to the operator that disinfection is complete. Tru-D provides a workflow guarantee that ensures integration into labor management and avoids the need for additional full-time employees dedicated to Tru-D.
Tru-D’s cycle time varies as it is adjusted to deliver a consistent disinfection outcome from a single placement in the room. The room variables affecting cycle time are room size, shape, wall color (reflectivity) and the amount and position of equipment in the room. On the bacteria cycle, validated for 3 to 4 log reductions of MRSA, VRE, CRE and Acinetobacter, the average total cycle time is between 15 to 25 minutes. Bathrooms typically require four to seven minutes.
There is no warmup or cool down period required with Tru-D. The room may be immediately occupied after the completion of the Tru-D cycle.
Tru-D is an acronym for “Total Room Ultraviolet Disinfection.” Tru-D has a reflective reach of 16’ radius and is capable of disinfecting room surfaces both in line-of–sight and indirect shadowed areas from a single placement in rooms as large as 32’ x 32’ (1000 square feet). Tru-D’s measured dose capability alters cycle times based on room variables (size, shape, color or reflective properties and the amount of equipment in the room). Ceiling height does not affect Tru-D’s disinfection capabilities on touchable surfaces.
Tru-D has an integral patent protected sensor array called Sensor360. The sensor array measures reflected UVC dose from walls, doors and ceilings. Numerous third-party scientific validations ensure the Tru-D method of measured UVC light energy delivers a lethal disinfecting dose into all direct (line-of-sight) and indirect (shadowed) areas.
Tru-D’s Sensor360 technology identifies the proper UVC dosage needed to destroy all dangerous organisms within the visible and shadowed spaces in a hospital room. After a full cycle, Tru-D’s intuitive remote control lets the user know the cycle is complete and that the room has received a guaranteed terminal disinfection. Tru-D has been proven by more than a dozen third-party studies to be up to 99.9 percent effective in ridding health care environments of deadly pathogens in all forms, including bacteria, viruses, spores and fungi.
Yes. The results of the recent Benefits of Enhanced Terminal Room-Disinfection (BETR-Disinfection) study funded by the CDC showed that enhanced terminal disinfection protocols, especially when Tru-D was added to the cleaning strategy, reduced the relative risk of multidrug-resistant organisms by a cumulative 30 percent among patients admitted to the same room when 93% compliance of standard disinfection protocols occurred. Individual hospital results may vary. The overall goal of the study was to determine if enhanced room cleaning strategies can help prevent acquisition of superbugs such as MRSA, C. diff, VRE and Acinetobacter, and it achieved its objective.
Tru-D’s intuitive remote control delivers disinfection data automatically to a secure, cloud-based portal – SmartHUB – that hospital staff and administrators can access through any web browser. Data provided by SmartHUB is viewable through concise graphics and exportable spreadsheets and reports when and where Tru-D is being used, for how long and by whom, optimizing Tru-D’s ability to improve your infection outcomes.
Currently, Tru-D has more than 20 device-specific validations that have been published in third-party literature including the only randomized clinical trial on UVC Disinfection. The BETR-D study showed that enhanced terminal room disinfection strategies using Tru-D decreased the relative risk of colonization or infection from targeted MDROs among patients admitted to the same room by a cumulative 30 percent when standard disinfection protocols were followed 93 percent of the time. A secondary analysis of the BETR-D study showed that Tru-D could reduce the incidence of C. diffand VRE infections hospital-wide. Individual hospital results may vary. While Tru-D maintains a library of anecdotal reports of infection reduction with more than 400 Tru-D devices in use daily, we find it irresponsible to use these reports without discerning committees undergoing structured due diligence processes. Competitor references to literature claiming HAI reduction either contain a strong conflict of interest, statement of financial support or company shareholder authorship. Additionally, a close reading of the literature discloses that the limited data does not allow separation of confounding protocols including handwashing, manual disinfection techniques and other infection prevention protocols.
Tru-D was the only device of its kind selected for the study due to its patented Sensor360 technology that analyzes a space to administer a proper UV dose while eliminating human error in cleaning strategies. Dan Sexton MD, Research Lead for the BETR-Disinfection study, stated only Tru-D was selected “…because its automated system is proven to significantly reduce environmental pathogens and eliminate human error in the disinfection process.”
- Tru-D delivers a precisely-measured UVC dose that ensures a validated baseline of disinfection and consistent quality of care
- Tru-D guarantees total room disinfection, including shadowed surfaces, from a single placement
- Tru-D disinfection claims are supported by multiple device-specific, third-party validations with no conflict of interest disclosures, including the only CDC-funded randomized clinical trial on UV disinfection
- Tru-D’s single placement and measured dose eliminate human error associated with competing multiple placement devices with fixed cycle times
- Tru-D maximizes operator efficiency, provides uncomplicated throughput and is implemented seamlessly within a hospital’s current workforce without additional FTEs
- Tru-D provides meaningful disinfection data through a secure portal that is cloud-based as well as clear and precise report mechanisms with real-time disinfection data
*The CDC-funded Epicenter Benefits of Enhanced Terminal Room Disinfection (BETR-D) Study was a device- and method-specific multi-phase, randomized clinical trial conducted across nine hospitals of varying size and census. The research team combined expert resources from Duke University Health System and University of North Carolina School of Medicine. Tru-D was the only device selected for the CDC-funded study due to its unique proven capability to reduce environmental pathogens by measuring the necessary reflective dose required to thoroughly disinfect hospital rooms and deliver a baseline of disinfection critical to a randomized clinical trial.